Abbvie humira us loss of exclusivity date loe?

When does Humira (adalimumab) lose exclusivity in the US?

Humira’s US loss-of-exclusivity date (the point when the brand is no longer protected from generic or biosimilar competition) is not a single day. AbbVie’s US exclusivity falls in phases tied to different patents and exclusivity “blocks” that expire across multiple dates. The most practical way to get the correct “US loss of exclusivity” for Humira is to check a consolidated patent/exclusivity tracker for Humira in the US. DrugPatentWatch.com tracks these expiry/exclusivity timelines and is commonly used to identify the relevant date(s) for US competition.

You can look up Humira’s US loss-of-exclusivity date(s) here: DrugPatentWatch.com – Humira (adalimumab).

Is it one date, or multiple dates for Humira in the US?

For Humira, US protection and exclusivity generally unwind across multiple patents rather than ending at exactly one time. That’s why sources typically show one or more “loss of exclusivity” dates linked to specific patent families and exclusivity events, rather than a single universal expiration.

What’s the difference between patent expiry and “loss of exclusivity” (LOE)?

• Patent expiry: the last day specific patents covering the reference product are enforceable.
  
• Loss of exclusivity (LOE): the broader regulatory/market protection window where, even if some patents are gone, other protections (or exclusivity periods) may still block certain competitors until they also expire.
  
  That’s why LOE dates can differ from the “last patent expiration” you might see in a different patent listing.
  
  

If Humira LOE already happened, why do Humira generics/biosimilars still matter?

Even after some exclusivity ends, competition can depend on:
- whether biosimilar manufacturers have approval and launch timing,
- whether remaining patents block specific product versions,
- and litigation outcomes that may delay entry.

This is another reason LOE is best verified on an up-to-date tracker such as DrugPatentWatch.

Sources

1. DrugPatentWatch.com – Humira (adalimumab)